Johnson & Johnson offered $8.9 billion to settle years-old lawsuits claiming that its talcum powder products caused cancer.
The New Jersey-based pharmaceutical giant described their proposal, which still needs a bankruptcy court’s approval, as an equitable and efficient resolution to all claims arising from cosmetic talc litigation.
If approved by the bankruptcy court and a majority of the claimants, the $8.9 billion deal would rank alongside those reached by cigarette corporations and opioid producers as one of the largest product liability settlements ever in the US
Thousands of claims have been filed against J&J because of talcum powder that may have contained traces of asbestos and was linked to ovarian cancer.
The company has never acknowledged wrongdoing, but as of May 2020, it no longer sells its talc-based baby powder in the US and Canada.
The $8.9 billion would be paid to the tens of thousands of claimants over 25 years through a J&J subsidiary, LTL Management LLC, which was set up to address the claims and has filed for bankruptcy protection.
A previous settlement involving LTL was rejected by an appellate court.


Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins
Hanwha Offers Up to $1.2 Billion for Austal US Business
Juan Orlando Hernandez Seeks Dismissal of Honduras Charges After Trump Pardon
Singapore Raises 2026 GDP Growth Forecast as AI Demand Fuels Economy
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises
Wall Street Slips as Oil Prices Surge 5% on Iran-Hormuz Uncertainty
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme
FCC Moves to Ban Imports of Foreign Military-Grade Drones Over Security Risks
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies
Japan Posts First Current Account Deficit in 17 Months as Dividend Payments Surge
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
Asian Stocks Rise as Weak US Jobs Data Eases Fed Rate Hike Fears
EEOC Drops Penn Subpoena in Antisemitism Probe, Investigation Continues
Gold Prices Rise as Fed Rate Hike Bets Ease
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 



